A multigene mutation classification of 468 colorectal cancers reveals a prognostic role for APC

Michael J. Schell(Moffitt Cancer Center), Mingli Yang(Spartanburg Regional Healthcare System), Jamie K. Teer(Moffitt Cancer Center), Fang Yin Lo(LabCorp (United States)), Anup Madan(LabCorp (United States)), Domenico Coppola(Moffitt Cancer Center), Álvaro N.A. Monteiro(Moffitt Cancer Center), Michael Nebozhyn(Merck & Co., Inc., Rahway, NJ, USA (United States)), Binglin Yue(Moffitt Cancer Center), Andrey Loboda(Merck & Co., Inc., Rahway, NJ, USA (United States)), Gabriel A. Bien‐Willner(Opexa Therapeutics (United States)), Danielle M. Greenawalt(Merck & Co., Inc., Rahway, NJ, USA (United States)), Timothy J. Yeatman(Spartanburg Regional Healthcare System)
Nature Communications
June 15, 2016
Cited by 216Open Access
Full Text

Abstract

Colorectal cancer (CRC) is a highly heterogeneous disease, for which prognosis has been relegated to clinicopathologic staging for decades. There is a need to stratify subpopulations of CRC on a molecular basis to better predict outcome and assign therapies. Here we report targeted exome-sequencing of 1,321 cancer-related genes on 468 tumour specimens, which identified a subset of 17 genes that best classify CRC, with APC playing a central role in predicting overall survival. APC may assume 0, 1 or 2 truncating mutations, each with a striking differential impact on survival. Tumours lacking any APC mutation carry a worse prognosis than single APC mutation tumours; however, two APC mutation tumours with mutant KRAS and TP53 confer the poorest survival among all the subgroups examined. Our study demonstrates a prognostic role for APC and suggests that sequencing of APC may have clinical utility in the routine staging and potential therapeutic assignment for CRC.


Related Papers

No related papers found

Powered by citation graph analysis